HEMO2life® improves renal function independent of cold ischemia time in kidney recipients: A comparison with a large multicenter prospective cohort study
- 24 December 2021
- journal article
- clinical trial
- Published by Wiley in Artificial Organs
- Vol. 46 (4) , 597-605
Abstract
Background: M101 is an extracellular hemoglobin isolated from a marine lugworm and is present in the medical device HEMO2life®. The clinical investigation OXYOP was a paired kidney analysis (n = 60) designed to evaluate the safety and performance of HEMO2life® used as an additive to preservation solution in renal transplantation. The secondary efficacy endpoints showed less delayed graft function (DGF) and better renal function in the HEMO2life® group but due to the study design cold ischemia time (CIT) was longer in the contralateral kidneys.Methods: An additional analysis was conducted including OXYOP patients and patients from the ASTRE database (n = 6584) to verify that the decrease in DGF rates observed in the HEMO2life® group may not be due solely to the shorter CIT but also to HEMO2life® performance. Kaplan–Meier estimate curves of cumulative probability of achieving a creatinine level below 250 µmol/L were generated and compared in both groups. A Cox model was used to test the effect of the explanatory variables (use of HEMO2life® and CIT). Finally, a bootstrap strategy was used to randomly select smaller samples of patients and test them for statistical comparison in the ASTRE database.Results: Kaplan–Meier estimate curves confirmed the existence of a relation between DGF and CIT and Cox analysis showed a benefit in the HEMO2life® group regardless of the associated CIT. Boostrap analysis confirmed these results.Conclusions: The present study suggested that the better recovery of renal function observed among kidneys preserved with HEMO2life® in the OXYOP study is a therapeutic benefit of this breakthrough innovative medical device.Keywords
This publication has 34 references indexed in Scilit:
- Benefits of active oxygenation during hypothermic machine perfusion of kidneys in a preclinical model of deceased after cardiac death donorsJournal of Surgical Research, 2013
- Supplementation With a New Therapeutic Oxygen Carrier Reduces Chronic Fibrosis and Organ Dysfunction in Kidney Static PreservationAmerican Journal of Transplantation, 2011
- The two layer method does not improve the preservation of porcine kidneysMedical Science Monitor, 2011
- A Risk Prediction Model for Delayed Graft Function in the Current Era of Deceased Donor Renal TransplantationAmerican Journal of Transplantation, 2010
- Similar Outcomes with Different Rates of Delayed Graft Function May Reflect Center Practice, Not Center PerformanceAmerican Journal of Transplantation, 2009
- Marked variation in the definition and diagnosis of delayed graft function: a systematic reviewNephrology Dialysis Transplantation, 2008
- Arenicola marina extracellular hemoglobin: a new promising blood substituteBiotechnology Journal, 2006
- Quaternary Structure of the Extracellular Haemoglobin of the Lugworm Arenicola marinaEuropean Journal of Biochemistry, 1997
- DELAYED GRAFT FUNCTION, ACUTE REJECTION, AND OUTCOME AFTER CADAVER RENAL TRANSPLANTATIONTransplantation, 1995
- A NEW, SIMPLE METHOD FOR COLD STORAGE OF THE PANCREAS USING PERFLUOROCHEMICALTransplantation, 1988